Search

Displaying results 8501 - 8510 of 8547 in total
  1. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions.

  2. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    As of May 2013 no new trials had been registered.

  3. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small

  4. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy

  5. Drug

    Ramosetron

    go.drugbank.com/drugs/DB09290
    Investigational

    It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.

  6. Drug

    Imidacloprid

    go.drugbank.com/drugs/DB11421
    ExperimentalVet approved

    It is marketed as pest control, seed treatment, an insecticide spray, termite control, flea control, and a systemic insecticide.

  7. Drug

    Geneticin

    go.drugbank.com/drugs/DB04263
    Experimental

    Geneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea.

  8. Drug

    Anti-SARS-CoV-2 immunoglobulin

    go.drugbank.com/drugs/DB16360
    Investigational

    from [COVID-19 convalescent plasma](https://go.drugbank.com/drugs/DB15692) but contains more SARS-CoV-2 neutralizing antibodies than found in [convalescent plasma](https://go.drugbank.com/drugs/DB15692) as

  9. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

  10. Drug

    Tefidsogene civaparvovec

    go.drugbank.com/drugs/DB16789
    Investigational

    Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing.